Scienture (NASDAQ:SCNX – Get Free Report) and Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.
Earnings and Valuation
This table compares Scienture and Tvardi Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Scienture | $430,000.00 | 29.10 | -$41.51 million | ($2.10) | -0.15 |
| Tvardi Therapeutics | $7.14 million | 3.01 | -$18.21 million | ($2.79) | -0.58 |
Insider and Institutional Ownership
5.7% of Scienture shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 21.4% of Scienture shares are held by insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and target prices for Scienture and Tvardi Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Scienture | 1 | 0 | 1 | 0 | 2.00 |
| Tvardi Therapeutics | 1 | 1 | 6 | 1 | 2.78 |
Scienture currently has a consensus price target of $1.50, suggesting a potential upside of 392.29%. Tvardi Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 1,018.01%. Given Tvardi Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Tvardi Therapeutics is more favorable than Scienture.
Volatility & Risk
Scienture has a beta of 3.25, indicating that its share price is 225% more volatile than the S&P 500. Comparatively, Tvardi Therapeutics has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500.
Profitability
This table compares Scienture and Tvardi Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Scienture | N/A | -53.51% | -42.47% |
| Tvardi Therapeutics | N/A | -145.40% | -91.11% |
About Scienture
Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.
About Tvardi Therapeutics
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Receive News & Ratings for Scienture Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scienture and related companies with MarketBeat.com's FREE daily email newsletter.
